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Minority variant human immunodeficiency virus type 1 (HIV-
1) nonnucleoside reverse transcriptase inhibitor (NNRTI)
resistance mutations are associated with an increased risk of
virological failure during treatment with NNRTI-containing
regimens. To determine whether individuals to whom variants
with isolated NNRTI-associated drug resistance were trans-
mitted are at increased risk of virological failure during treat-
ment with a non-NNRTI–containing regimen, we identified
minority variant resistance mutations in 33 individuals with
isolated NNRTI-associated transmitted drug resistance and 49
matched controls. We found similar proportions of overall and
nucleoside reverse transcriptase inhibitor–associated minority
variant resistance mutations in both groups, suggesting that
isolated NNRTI-associated transmitted drug resistance may not 
be a risk factor for virological failure during treatment with a
non-NNRTI–containing regimen.
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Standard genotypic resistance testing using Sanger sequencing 
is recommended upon diagnosis of human immunodeficiency 
virus type 1 (HIV-1) infection to identify individuals to whom 
drug-resistant HIV-1 was transmitted. Sanger sequencing typ-
ically detects drug resistance mutations (DRMs) present in 
at least 20%–30% of circulating plasma viruses [1]. However, 
DRMs present below this threshold, commonly referred to as 
“minority variant DRMs,” have been shown to increase the risk 
of virological failure during an initial nonnucleoside reverse 
transcriptase inhibitor (NNRTI)–containing regimen [2].
The prevalence of transmitted drug resistance (TDR) in the 
United States ranges from 10% to 20%, with NNRTIs being 
the most commonly affected drug class [3, 4]. Nucleoside 
reverse transcriptase inhibitor (NRTI)–associated and NNRTI-
associated DRMs emerge commonly in patients with virological 
failure during an NNRTI-containing regimen. However, in the 
absence of selective antiretroviral pressure, transmitted NRTI-
associated DRMs decay more rapidly than transmitted NNRTI-
associated DRMs [5]. Therefore, we investigated whether 
individuals with NNRTI-associated TDR detected by Sanger 
sequencing are more likely than those without TDR detected 
by Sanger sequencing to harbor minority variant DRMs that 
would increase their risk of virological failure even during a 
non-NNRTI–containing regimen.
To determine whether TDR is associated with an increased 
prevalence of minority variant DRMs, we performed Illumina 
next-generation sequencing of a portion of the reverse tran-
scriptase coding region from plasma samples collected before 
antiretroviral therapy from individuals with isolated NNRTI-
associated TDR and individuals without TDR. For accurate 
identification and quantification of minority variants, we used 
the Primer ID method, which corrects for polymerase chain 
reaction (PCR) bias and for PCR and sequencing errors and 
reveals the sampling depth of the viral population [6].
METHODS
Study Population
The study population included HIV-1–infected, antiretroviral-na-
ive individuals in the Kaiser Permanente Medical Care Program–
Northern California (KPNC) undergoing Sanger sequencing at 
Stanford Health Care Diagnostic Virology Laboratory between 
April 2004 and September 2012. The TDR prevalence in this pop-
ulation during the study period was 12.5%. The TDR group com-
prised 33 individuals with isolated NNRTI-associated TDR, defined 
as having variants with ≥1 NNRTI-associated surveillance DRM 
but no NRTI-associated or protease inhibitor–associated surveil-
lance DRMs detected by Sanger sequencing [7]. The control group 
comprised 49 antiretroviral-naive individuals without any TDR by 
Sanger sequencing who were matched to the TDR group for HIV-1 
RNA level, CD4+ T-cell count, sampling year, and antiretroviral 
regimen where possible. Additional inclusion criteria were a viral 
load of >10 000 copies/mL and an available cryopreserved sample 
for analysis by next-generation sequencing. The Stanford University 
and KPNC institutional review boards approved this study.
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RNA extracted from plasma was reverse transcribed to com-
plementary DNA, using SuperScript One-Step reverse tran-
scription PCR with Platinum Taq (ThermoFisher Scientific, 
Waltham MA). AmpliTaq DNA polymerase was used for nested 
PCR analysis. Bidirectional sequencing encompassing protease 
and the first 250 codons of reverse transcriptase was performed 
using Big Dye Terminator Cycle Sequencing with electro-
phoretic resolution of products on an ABI 3730 sequencer 
(ThermoFisher Scientific). The GenBank accession numbers for 
the Sanger sequences are in the Supplementary Materials.
Primer ID Illumina Next-Generation Sequencing
Primer ID Illumina/MiSeq sequencing was performed using a pre-
viously published protocol [6]. RNA was extracted from plasma, 
using the QIAamp viral RNA mini kit (Qiagen, Germantown, 
MD). Barcoded primers (Primer IDs) and Superscript III First 
Strand Synthesis System (Invitrogen, Carlsbad, CA) were used 
to generate complementary DNA (primer sequences are in the 
Supplementary Materials). The complementary DNA was puri-
fied to remove the unincorporated Primer ID oligos and then 
used as a template in 2 rounds of PCR, with MiSeq-indexed 
primers incorporated in the second round of PCR. Sequencing 
libraries were purified, quantified, and pooled for sequencing 
by Illumina MiSeq 300-base paired-end platform. The Illumina 
bcl2fastq pipeline (v.1.8.4) was used to for initial processing of 
sequence data. The Primer ID consensus pipeline was then used 
to create template consensus sequences for each starting viral 
RNA genome by pooling reads with identical Primer IDs, with 
the number of unique Primer IDs in a run defining the sam-
pling depth of the viral RNA population [6] (available at: https://
github.com/SwanstromLab/PID). The HXB2 numbering for the 
sequenced regions was 2648–3257 (reverse transcriptase codons 
35–235). To distinguish mutations present in the viral RNA from 
the low rate of residual error, a Poisson threshold set at 10 times 
the frequency of the residual error was determined for each sam-
ple. Additionally, all template consensus sequences containing 
stop codons were excluded [6].
Statistical Analysis
We defined minority variant mutations as amino acid differ-
ences from the consensus B sequence that were detected by 
next-generation sequencing but not Sanger sequencing. We 
compared the prevalence and frequencies of minority variant 
DRMs between the TDR and control groups, using the Fisher 
exact test and Wilcoxon rank sum test, respectively. We defined 
potential APOBEC-associated DRMs as DRMs that could result 
from G→A substitutions within the canonical APOBEC3F 
(GA→AA) or APOBEC3G (GG→AG) dinucleotide con-
texts: D67N, E138K, M184I, G190S/E, and M230I [8]. Human 
APOBEC3F/G enzymes are retroviral restriction factors that 
generate de novo viral mutations in a characteristic sequence 
context to impair viral fitness.
We performed 2 analyses of clinical outcomes: (1) we com-
pared the proportions of individuals with virological failure 
between the TDR and control groups, and (2) we compared the 
proportions of individuals with virological failure between indi-
viduals with and those without minority variant DRMs confer-
ring reduced susceptibility to any antiretroviral in the regimen 
they received. Reduced susceptibility to an antiretroviral was 
defined as intermediate or high-level resistance according to the 
Stanford HIV Drug Resistance Database interpretation system 
(version 8.2) [9]. Virological failure was defined as a confirmed 
HIV RNA level of >75 copies/mL at week 48. The Fisher exact 
test was used for both comparisons.
RESULTS
Characteristics of the TDR and Control Groups
Overall, 90% of study individuals were male, 55% were white, 
and the median age was 42 years. The median CD4+ T-cell count 
was 339 cells/mm3, and the median viral load was 4.8 log copies/
mL. Fifty percent and 35% of patients initiated a regimen con-
taining raltegravir or boosted atazanavir, respectively. Eighty-
eight percent of regimens included the NRTIs emtricitabine and 
tenofovir. The median year of pretherapy Sanger sequencing 
was 2010. Demographic and clinical characteristics were sim-
ilar between the TDR and control groups, with the exception 
that more control individuals initiated a regimen not containing 
raltegravir or boosted atazanavir (Supplementary Table 1).
Primer ID Illumina Sampling Depth
The median number of template consensus sequences was 619 
overall (interquartile range [IQR], 257–1462). It was higher 
in the control group (1045; IQR, 394–1663) than in the TDR 
group (445; IQR, 169–960; P = .03, by the Wilcoxon rank sum 
test). The median lower limit of detection of a minority vari-
ant with 95% confidence for a sample was 0.5% overall (IQR, 
.2%–1.2%), 0.7% in the TDR group (IQR, .3%–1.8%), and 0.3% 
in the control group (IQR, .2%–.8%; P = .03, by the Wilcoxon 
rank sum test). The lowest limit of detection was 0.04% in the 
TDR group and 0.03% in the control group.
Distribution of Drug Resistance Mutations
Overall, 110 DRMs were detected in 66 of 82 study individu-
als (80%). Of the 110 DRMs, 35 were NNRTI-associated DRMs 
detected by Sanger sequencing among the 33 individuals in 
the TDR group. Each of these mutations was also detected by 
next-generation sequencing. The additional 75 DRMs were 
minority variants, as they were detected only by next-generation 
sequencing. Overall, minority variant DRMs were detected in 
49 study individuals (60%). The most-common minority vari-
ant DRMs were G190E (in 16 individuals), K219R (in 11), and 
K101E, M184I, and K219E (in 5 each; Table 1). Figure 1 shows 
that there were 2 main distributions of DRMs: those occurring 
at low frequencies detectable only by next-generation sequenc-
ing and those occurring at high frequencies that were detected 
by both sequencing methods. Among the 75 minority variant 
DRMs, 48 occurred at frequencies of 0.1%–0.3%, whereas 27 
occurred at frequencies of 0.4%–14%.
Comparison of Minority Variants in the TDR and Control Groups
There was no difference in the proportion of individuals in the 
TDR (19 of 33 [58%]) and control (30 of 49 [61%]) groups with 
minority variant DRMs (P  =  .82; Table  1). NRTI-associated 
minority variant DRMs were present in 39% of individuals 
overall, including 10 (30%) in the TDR group and 22 (45%) in 
the control group (P =  .25). NNRTI-associated minority vari-
ant DRMs were present in 37% of individuals overall, including 
11 (33%) in the TDR group and 19 (39%) in the control group 
(P = .65). Combined NRTI-associated plus NNRTI-associated 
minority variant DRMs were present in 16% of individuals 
overall, including 2 (6%) in the TDR group and 11 (22%) in the 
control group (P = .06). There was no difference in the median 
frequency of minority variant DRMs observed in the TDR and 
control groups (0.2% in both groups; P = .82).
Of the 75 minority variant DRMs, 24 (32%) were potential 
APOBEC-associated DRMs, including G190E in 16 individuals, 
M184I in 5 individuals, and D67N in 3 individuals. There was no 
difference in the proportions of potential APOBEC-associated 
minority variant DRMs between the TDR and control groups.
Virological Outcome
There was no difference in the proportions of individuals with 
virological failure between the TDR and control groups (2 of 33 
vs 5 of 49; P = .70). Poor medication adherence was documented 
in 4 of 7 individuals with virological failure. Two individuals in 
the control group and none in the TDR group underwent repeat 
Sanger sequencing. The DRM M184V was detected during viro-
logical failure in one of the control individuals who lacked base-
line minority variant DRMs.
Two of 33 individuals in the TDR group and 8 of 49 in the 
control group had minority variant DRMs associated with 
intermediate or high-level resistance to ≥1 antiretroviral in 
their treatment regimen (P = .30). One of the 8 patients in 
Table  1. Minority Variant Drug Resistance Mutations (DRMs) in the 
Control Group and the Group With Transmitted Drug Resistance (TDR)
Variable Control Group (n = 49) TDR Group (n = 33) Pa
Minority variant DRM pattern, patients, no. (%)
 Any 30 (61) 19 (58) .82
NRTI only 22 (45) 10 (30) .25
NNRTI only 19 (39) 11 (33) .65
NNRTI and NRTI 11 (22) 2 (6) .06
Minority variant DRMs, median frequency, % (number of occurrences)
Any 0.2 (48) 0.2 (27) .82
NRTI
Overall 0.2 (25) 0.2 (16) .29
M41L 0 0.3 (1)
K65R 0 0.2 (1)
D67Nb 0.2 (3) 0
K70E 0 0.1 (1)
K70R 0 0.1 (1)
V75M 0.1 (1) 0
M184Ib 0.4 (5) 0
M184V 0.1 (1) 0.6 (1)
L210W 11.4 (1) 0
T215I 0.2 (2) 0.5 (2)
T215S 0.2 (3) 0
K219E 1.1 (1) 0.1 (4)
K219N 0.7 (1) 0
K219Q 0.8 (1) 0
K219R 0.2 (6) 0.4 (5)
NNRTI
Overall 0.2 (23) 0.5 (11) .10
K101E 0.2 (3) 5.7 (2)
K103N 4.4 (1) 0.3 (1)
K103S 0 0.9 (4)
Y181C 0.2 (3) 0.1 (1)
Y181V 0.2 (1) 0
Y188H 0.1 (1) 0
G190Eb 0.2 (13) 1.2 (3)
P225H 1.5 (1) 0
Frequency is calculated as the percentage of an individual’s virus population that bears a 
specific DRM.
Abbreviations: NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside 
reverse transcriptase inhibitor.
aComparisons of the proportions of patients with a particular minority variant DRM pattern 
between the control and TDR groups were made using the Fisher exact test. Comparisons 
of the DRM frequencies among those individuals with a particular DRM in the control and 
TDR groups were made using the Wilcoxon rank sum test.
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Figure 1. Histogram of drug resistance mutation (DRM) frequency, by method of 
sequencing. The histogram plots the number of DRMs detected at each frequency 
(percentage of the total virus population). DRMs in red were detected only by 
next-generation sequencing (NGS), and those in blue were detected by both Sanger 
sequencing and NGS.
the control group with a pretherapy minority variant DRM 
(M184I at a frequency of 0.1%) developed virological fail-
ure during treatment with a boosted atazanavir-based reg-
imen. Repeat resistance testing was not performed, and the 
individual achieved resuppression following substitution of 
lopinavir for atazanavir.
DISCUSSION
We used Primer ID Illumina next-generation sequencing to 
quantify the number of minority variant DRMs in 33 antiret-
roviral-naive individuals with isolated NNRTI-associated 
TDR detected by Sanger sequencing and 49 matched con-
trols without TDR. The overall proportion of individuals with 
minority variant DRMs was 60%. This proportion is higher 
than that reported in previous next-generation sequenc-
ing studies, which have reported detecting minority variant 
DRMs in 20%–35% of antiretroviral-naive individuals [10]. 
Previous next-generation sequencing studies, however, gen-
erally ignored minority variant DRMs detected at levels of 
<1.0% because of the high probability that, in the absence of 
a method such as Primer ID, variants detected at a lower fre-
quency include errors introduced during PCR amplification 
and sequencing [11].
The minority variant DRMs we observed likely represent a 
combination of transmitted DRMs that faded to levels no lon-
ger detectable by Sanger sequencing and de novo mutations 
resulting from HIV-1 reverse transcriptase misincorporation or 
APOBEC-mediated editing. Indeed, most of the DRMs in this 
study had a frequency either close to 100% or close to 0%. This 
bimodal distribution is consistent with 2 sources of DRMs. The 
finding that nearly one third of the minority variant DRMs were 
potential APOBEC-associated DRMs suggests that many of 
these were de novo mutations. In particular, G190E, which was 
present in 16 individuals, is rarely detected by Sanger sequenc-
ing and is extremely unfit [12].
Previous noncomparative studies have shown that indi-
viduals with TDR detected by Sanger sequencing may have 
additional minority variant DRMs [13, 14]. In this study, 
however, we found that individuals with TDR were not more 
likely than those without TDR to have additional minority 
variant DRMs. A potential explanation for the similar preva-
lence of minority variant DRMs among those with and those 
without NNRTI-associated TDR is that minority variant 
DRMs resulting from de novo mutation are likely to be evenly 
distributed among individuals with and those without TDR, 
potentially obscuring differences arising from the fading of 
transmitted DRMs.
The absence of an excess of minority variant DRMs among 
individuals with isolated NNRTI-associated TDR may help 
explain previous reports that antiretroviral-naive individ-
uals with isolated NNRTI-associated TDR who receive a 
non-NNRTI-containing regimen achieve similar rates of viro-
logical suppression as compared to individuals without TDR 
[15]. However, our study was underpowered to assess the clini-
cal significance of minority variant DRMs because only 10 indi-
viduals had minority variant DRMs associated with reduced 
susceptibility to any of the antiretrovirals in their regimen.
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